These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35140119)

  • 1. Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem.
    Barnes-Weise J; Santos Rutschman A; Adler R
    J Epidemiol Community Health; 2022 Apr; 76(4):317-318. PubMed ID: 35140119
    [No Abstract]   [Full Text] [Related]  

  • 2. Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.
    Hawksbee L; McKee M; King L
    BMJ; 2022 Jan; 376():e067367. PubMed ID: 35101900
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovation alone won't end COVID-19.
    Amin T
    Nat Hum Behav; 2022 Feb; 6(2):172-173. PubMed ID: 35102360
    [No Abstract]   [Full Text] [Related]  

  • 4. Temporary waiver of intellectual property on Covid-19 vaccines: toward the creation of a better, post-pandemic society.
    Del Castillo FA
    J Public Health (Oxf); 2021 Sep; 43(3):e559-e560. PubMed ID: 34056662
    [No Abstract]   [Full Text] [Related]  

  • 5. Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic.
    Altindis E
    Expert Rev Vaccines; 2022 Apr; 21(4):427-430. PubMed ID: 34878957
    [No Abstract]   [Full Text] [Related]  

  • 6. Intellectual property waiver for covid-19 vaccines will advance global health equity.
    Erfani P; Binagwaho A; Jalloh MJ; Yunus M; Farmer P; Kerry V
    BMJ; 2021 Aug; 374():n1837. PubMed ID: 34344728
    [No Abstract]   [Full Text] [Related]  

  • 7. A patent waiver on COVID vaccines is right and fair.
    Nature; 2021 May; 593(7860):478. PubMed ID: 34035532
    [No Abstract]   [Full Text] [Related]  

  • 8. Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?
    Burki TK
    Lancet Respir Med; 2021 Jul; 9(7):e64. PubMed ID: 34029536
    [No Abstract]   [Full Text] [Related]  

  • 9. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waiver of Intellectual Property Rights on COVID-19 vaccine roll out.
    Cabatbat KPM
    J Public Health (Oxf); 2022 Jun; 44(2):e338. PubMed ID: 34164670
    [No Abstract]   [Full Text] [Related]  

  • 11. What's yours is ours: waiving intellectual property protections for COVID-19 vaccines.
    Jecker NS; Atuire CA
    J Med Ethics; 2021 Sep; 47(9):595-598. PubMed ID: 34233956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network analysis of COVID-19 mRNA vaccine patents.
    Gaviria M; Kilic B
    Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitating Access to a COVID-19 Vaccine through Global Health Law.
    Gostin LO; Karim SA; Mason Meier B
    J Law Med Ethics; 2020 Sep; 48(3):622-626. PubMed ID: 33021168
    [No Abstract]   [Full Text] [Related]  

  • 15. Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine.
    Sekalala S; Forman L; Hodgson T; Mulumba M; Namyalo-Ganafa H; Meier BM
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34253631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What next for a COVID-19 intellectual property waiver?
    Zarocostas J
    Lancet; 2021 May; 397(10288):1871-1872. PubMed ID: 34022975
    [No Abstract]   [Full Text] [Related]  

  • 17. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New WTO leader faces COVID-19 challenges.
    Zarocostas J
    Lancet; 2021 Feb; 397(10276):782. PubMed ID: 33640051
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology.
    Meijer M; Verschuuren M; Weggen E
    Eur J Public Health; 2021 Oct; 31(5):925-926. PubMed ID: 34473255
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.